Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half
This post was originally published on this siteBiogen is slashing the price of its controversial new Alzheimer’s disease treatment Aduhelm in half in a bid to revive a product launch that has stalled in part because of a backlash over the drug’s cost.
Democrats Reach Deal to Control Drug Prices in Social Policy Bill
This post was originally published on this siteThe provision would, for the first time, allow the government to negotiate prices for some medicines covered by Medicare.
